Skip to content

The CSTME Associates With the Prognosis of Stage II and III Colorectal Cancer

The Tumor Microenvironment Collagen Signature (CSTME) Associates With the Prognosis of Stage II and III Colorectal Cancer : A Multi-Center Retrospective Observational Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05420415
Acronym
CRC23_CSTME
Enrollment
570
Registered
2022-06-15
Start date
2018-09-01
Completion date
2022-05-01
Last updated
2022-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

Colorectal cancer (CRC) is the second most commonly occurring cancer worldwide. Thirty-five percent of CRC patients are diagnosed at stage II/III, and their outcome differs even if they are in the same stage. Previous study found that the microenvironmental collagen is associated with tumor progression and metastasis. Whether tumor microenvironmental collagen signature is associated with colorectal cancer prognosis still remains unknown. We hypothesize that the tumor microenvironmental collagen signature of colorectal cancer is associated with prognosis.

Detailed description

Colorectal cancer (CRC) is the second most commonly occurring cancer worldwide. Thirty-five percent of CRC patients are diagnosed at stage II/III, and their outcome differs even if they are in the same stage. In the seed and soil theory proposed by Stephen Paget, tumor cells play the role of the seed, and the tumor microenvironment (TME) is the soil. TNM classification provides useful but uncomplete prognosis information in colorectal cancer. It lacks the assessment of the soil signature of tumor microenvironment. Previous study found that the microenvironmental collagen is associated with tumor progression and metastasis. Whether tumor microenvironmental collagen signature is associated with colorectal cancer prognosis still remains unknown. This study is a retrospective observational study performed in two centers. The main purpose of this study was to investigate whether the tumor microenvironment collagen signature (CSTME) can discriminate the 5-year DFS of stage II/III CRC patients, the secondary purpose is to compare the AUC (area under the receiver operating characteristic curve) of TNM stage+CSTME in predicting 5-year DFS with that of TNM stage alone. This study would introduce the tumor microenvironmental collagen signature into current colorectal cancer classification system, which would provide reference for clinical practice.

Interventions

OTHERCSTME

Tumor microenvironment collagen signature

Sponsors

Sixth Affiliated Hospital, Sun Yat-sen University
CollaboratorOTHER
Nanfang Hospital, Southern Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Pathologically diagnosed with colorectal cancer * TNM stages II and III (according to the 8th edition of AJCC Cancer Staging Manual) * Received radical tumor resection surgery

Exclusion criteria

* ASA grade 4 * Preoperative radiotherapy and/or chemotherapy * Hereditary colorectal cancer * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
5-year DFS5 years followup after surgery5-year disease free survival

Secondary

MeasureTime frameDescription
5-year OS5 years followup after surgery5-year overall survival

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026